ORLANDO, Fla., March 29, 2009 /PRNewswire-FirstCall via COMTEX/ ----Long-term data presented today from Abbott's (NYSE: ABT: 46.58, 0.1305, 0.28%) SPIRIT II clinical trial demonstrated that the clinical advantages of the XIENCE V(R: 28.26, -1.5492, -5.2%) Everolimus Eluting Coronary Stent System continued to increase between two and three years compared to the TAXUS(R: 28.26, -1.5492, -5.2%) Express2(TM: 65.48, -1.55, -2.31%) Paclitaxel-Eluting Coronary Stent System / TAXUS(R: 28.26, -1.5492, -5.2%) Liberte(TM: 65.48, -1.55, -2.31%) Paclitaxel-Eluting Coronary Stent System (TAXUS: undefined, undefined, undefined%). Both TAXUS Express2 (73 percent of lesions) and TAXUS Liberte (27 percent of lesions) were used as controls in the SPIRIT II trial. The data also showed that patients treated with XIENCE V continue to experience fewer heart attacks, deaths or repeat procedures at the target lesion compared to patients treated with TAXUS out to three years. The results from the SPIRIT II trial were presented during the i2 Summit at the American College of Cardiology's 58th annual scientific session in Orlando, Fla.
Between two and three years, Abbott's market-leading XIENCE V maintained a low cardiac death rate of 0.5 percent, while the observed cardiac death rate for TAXUS more than tripled during the same time period (1.3 percent at two years vs. 4.2 percent at three years)*. Similarly, XIENCE V maintained a low, single-digit rate of major adverse cardiac events (MACE: 0.78, 0.03, 4%) between two and three years (6.4 percent at two years vs. 6.4 percent at three years), while the observed MACE rate with TAXUS increased approximately 40 percent between two and three years (10.5 percent at two years vs. 14.9 percent at three years)*. MACE is an important composite clinical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (myocardial infarction or MI), or ischemia-driven target lesion revascularization (ID-TLR driven by lack of blood supply).
In addition, the SPIRIT II results demonstrated that XIENCE V continues to outperform TAXUS, with XIENCE V showing continued clinical benefits at three years, including an 88 percent reduction in the risk of cardiac death and a 57 percent reduction in the risk of MACE.
"In the clinical outcomes that matter most, such as heart attack, repeat procedure at the target lesion or death, XIENCE V demonstrated a consistent reduction compared to TAXUS out to three years," said Patrick W. Serruys, M.D., Ph.D., professor of Interventional Cardiology at Thoraxcentre, Erasmus University Hospital, Rotterdam, the Netherlands, and principal investigator of the SPIRIT II clinical trial. "What's even more impressive is that the clinical differences between XIENCE V and TAXUS continue to widen between two and three years, confirming the long-term safety and efficacy of XIENCE V."
In the 300-patient SPIRIT II trial, XIENCE V demonstrated the following key results at three years:
No comments:
Post a Comment